nodes	percent_of_prediction	percent_of_DWPC	metapath
Pergolide—CYP2D6—Lomustine—hematologic cancer	0.0275	0.0738	CbGbCtD
Pergolide—CYP2D6—Idarubicin—hematologic cancer	0.0245	0.0658	CbGbCtD
Pergolide—CYP2D6—Hydroxyurea—hematologic cancer	0.0208	0.0559	CbGbCtD
Pergolide—CYP3A4—Bexarotene—hematologic cancer	0.0188	0.0505	CbGbCtD
Pergolide—CYP2D6—Bortezomib—hematologic cancer	0.0181	0.0487	CbGbCtD
Pergolide—CYP3A4—Lomustine—hematologic cancer	0.0175	0.0469	CbGbCtD
Pergolide—CYP3A4—Busulfan—hematologic cancer	0.0175	0.0469	CbGbCtD
Pergolide—CYP3A4—Thiotepa—hematologic cancer	0.0156	0.0418	CbGbCtD
Pergolide—CYP2D6—Imatinib—hematologic cancer	0.0133	0.0356	CbGbCtD
Pergolide—CYP3A4—Methoxsalen—hematologic cancer	0.0121	0.0325	CbGbCtD
Pergolide—CYP2D6—Nilotinib—hematologic cancer	0.0121	0.0324	CbGbCtD
Pergolide—CYP2D6—Vinorelbine—hematologic cancer	0.012	0.0321	CbGbCtD
Pergolide—CYP3A4—Bortezomib—hematologic cancer	0.0115	0.0309	CbGbCtD
Pergolide—CYP3A4—Daunorubicin—hematologic cancer	0.011	0.0296	CbGbCtD
Pergolide—CYP3A4—Cytarabine—hematologic cancer	0.00972	0.0261	CbGbCtD
Pergolide—CYP3A4—Teniposide—hematologic cancer	0.00957	0.0257	CbGbCtD
Pergolide—CYP3A4—Ifosfamide—hematologic cancer	0.00883	0.0237	CbGbCtD
Pergolide—CYP3A4—Imatinib—hematologic cancer	0.00844	0.0227	CbGbCtD
Pergolide—CYP3A4—Ruxolitinib—hematologic cancer	0.00795	0.0213	CbGbCtD
Pergolide—CYP3A4—Nilotinib—hematologic cancer	0.00767	0.0206	CbGbCtD
Pergolide—CYP3A4—Vinorelbine—hematologic cancer	0.0076	0.0204	CbGbCtD
Pergolide—CYP2D6—Vinblastine—hematologic cancer	0.00737	0.0198	CbGbCtD
Pergolide—CYP3A4—Triamcinolone—hematologic cancer	0.00695	0.0187	CbGbCtD
Pergolide—CYP3A4—Dasatinib—hematologic cancer	0.00678	0.0182	CbGbCtD
Pergolide—CYP3A4—Mitoxantrone—hematologic cancer	0.00669	0.018	CbGbCtD
Pergolide—CYP3A4—Betamethasone—hematologic cancer	0.00597	0.016	CbGbCtD
Pergolide—CYP3A4—Prednisolone—hematologic cancer	0.00589	0.0158	CbGbCtD
Pergolide—CYP3A4—Prednisone—hematologic cancer	0.00556	0.0149	CbGbCtD
Pergolide—CYP2D6—Dexamethasone—hematologic cancer	0.00546	0.0147	CbGbCtD
Pergolide—CYP3A4—Irinotecan—hematologic cancer	0.00527	0.0142	CbGbCtD
Pergolide—CYP3A4—Vinblastine—hematologic cancer	0.00469	0.0126	CbGbCtD
Pergolide—CYP3A4—Vincristine—hematologic cancer	0.00461	0.0124	CbGbCtD
Pergolide—CYP2D6—Doxorubicin—hematologic cancer	0.00453	0.0122	CbGbCtD
Pergolide—CYP3A4—Etoposide—hematologic cancer	0.00422	0.0113	CbGbCtD
Pergolide—CYP3A4—Dexamethasone—hematologic cancer	0.00347	0.00932	CbGbCtD
Pergolide—CYP3A4—Doxorubicin—hematologic cancer	0.00288	0.00773	CbGbCtD
Pergolide—DRD5—hematopoietic system—hematologic cancer	0.00086	0.0959	CbGeAlD
Pergolide—DRD4—testis—hematologic cancer	0.000715	0.0798	CbGeAlD
Pergolide—HTR1A—hematopoietic system—hematologic cancer	0.000429	0.0479	CbGeAlD
Pergolide—ADRA1A—hematopoietic system—hematologic cancer	0.000396	0.0442	CbGeAlD
Pergolide—KCNH2—hematopoietic system—hematologic cancer	0.000382	0.0427	CbGeAlD
Pergolide—HTR2B—blood—hematologic cancer	0.000318	0.0354	CbGeAlD
Pergolide—ADRA2A—hematopoietic system—hematologic cancer	0.000301	0.0336	CbGeAlD
Pergolide—HTR2B—lung—hematologic cancer	0.000278	0.0311	CbGeAlD
Pergolide—ADRA1A—blood—hematologic cancer	0.000262	0.0293	CbGeAlD
Pergolide—HTR2A—hematopoietic system—hematologic cancer	0.000256	0.0286	CbGeAlD
Pergolide—KCNH2—blood—hematologic cancer	0.000253	0.0283	CbGeAlD
Pergolide—ADRA2C—blood—hematologic cancer	0.00025	0.0279	CbGeAlD
Pergolide—KCNH2—bone marrow—hematologic cancer	0.000245	0.0274	CbGeAlD
Pergolide—CYP3A4—hematopoietic system—hematologic cancer	0.000237	0.0264	CbGeAlD
Pergolide—CYP2D6—hematopoietic system—hematologic cancer	0.000233	0.026	CbGeAlD
Pergolide—ADRA2A—gonad—hematologic cancer	0.000229	0.0255	CbGeAlD
Pergolide—DRD2—lung—hematologic cancer	0.000225	0.0252	CbGeAlD
Pergolide—ADRA2C—lung—hematologic cancer	0.000219	0.0245	CbGeAlD
Pergolide—DRD2—testis—hematologic cancer	0.000213	0.0237	CbGeAlD
Pergolide—KCNH2—testis—hematologic cancer	0.00021	0.0234	CbGeAlD
Pergolide—ADRA2C—testis—hematologic cancer	0.000207	0.0231	CbGeAlD
Pergolide—ADRA2A—blood—hematologic cancer	0.000199	0.0223	CbGeAlD
Pergolide—HTR2A—gonad—hematologic cancer	0.000195	0.0217	CbGeAlD
Pergolide—HTR2B—lymph node—hematologic cancer	0.00019	0.0213	CbGeAlD
Pergolide—ADRA2A—lung—hematologic cancer	0.000175	0.0195	CbGeAlD
Pergolide—HTR2A—blood—hematologic cancer	0.00017	0.0189	CbGeAlD
Pergolide—ADRA2A—testis—hematologic cancer	0.000165	0.0184	CbGeAlD
Pergolide—CYP3A4—blood—hematologic cancer	0.000157	0.0175	CbGeAlD
Pergolide—CYP2D6—blood—hematologic cancer	0.000154	0.0172	CbGeAlD
Pergolide—KCNH2—lymph node—hematologic cancer	0.000152	0.017	CbGeAlD
Pergolide—ADRA2C—lymph node—hematologic cancer	0.00015	0.0167	CbGeAlD
Pergolide—HTR2A—lung—hematologic cancer	0.000149	0.0166	CbGeAlD
Pergolide—HTR2A—testis—hematologic cancer	0.00014	0.0157	CbGeAlD
Pergolide—CYP2D6—testis—hematologic cancer	0.000128	0.0143	CbGeAlD
Pergolide—ADRA2A—lymph node—hematologic cancer	0.00012	0.0133	CbGeAlD
Pergolide—Headache—Gemcitabine—hematologic cancer	2.54e-05	5.52e-05	CcSEcCtD
Pergolide—Nausea—Vincristine—hematologic cancer	2.54e-05	5.52e-05	CcSEcCtD
Pergolide—Rhinitis—Doxorubicin—hematologic cancer	2.54e-05	5.51e-05	CcSEcCtD
Pergolide—Hepatitis—Doxorubicin—hematologic cancer	2.53e-05	5.49e-05	CcSEcCtD
Pergolide—Pharyngitis—Doxorubicin—hematologic cancer	2.51e-05	5.45e-05	CcSEcCtD
Pergolide—Dyspepsia—Betamethasone—hematologic cancer	2.51e-05	5.45e-05	CcSEcCtD
Pergolide—Dyspepsia—Dexamethasone—hematologic cancer	2.51e-05	5.45e-05	CcSEcCtD
Pergolide—Oedema peripheral—Doxorubicin—hematologic cancer	2.49e-05	5.41e-05	CcSEcCtD
Pergolide—Dysgeusia—Methotrexate—hematologic cancer	2.49e-05	5.41e-05	CcSEcCtD
Pergolide—Asthenia—Etoposide—hematologic cancer	2.49e-05	5.4e-05	CcSEcCtD
Pergolide—Body temperature increased—Triamcinolone—hematologic cancer	2.48e-05	5.4e-05	CcSEcCtD
Pergolide—Oedema—Prednisone—hematologic cancer	2.48e-05	5.39e-05	CcSEcCtD
Pergolide—Decreased appetite—Dexamethasone—hematologic cancer	2.48e-05	5.38e-05	CcSEcCtD
Pergolide—Decreased appetite—Betamethasone—hematologic cancer	2.48e-05	5.38e-05	CcSEcCtD
Pergolide—Nausea—Mitoxantrone—hematologic cancer	2.47e-05	5.37e-05	CcSEcCtD
Pergolide—Nausea—Irinotecan—hematologic cancer	2.47e-05	5.37e-05	CcSEcCtD
Pergolide—Infection—Prednisone—hematologic cancer	2.47e-05	5.36e-05	CcSEcCtD
Pergolide—Back pain—Methotrexate—hematologic cancer	2.46e-05	5.34e-05	CcSEcCtD
Pergolide—Chills—Epirubicin—hematologic cancer	2.45e-05	5.33e-05	CcSEcCtD
Pergolide—Pruritus—Etoposide—hematologic cancer	2.45e-05	5.32e-05	CcSEcCtD
Pergolide—Shock—Prednisone—hematologic cancer	2.44e-05	5.31e-05	CcSEcCtD
Pergolide—Arrhythmia—Epirubicin—hematologic cancer	2.44e-05	5.3e-05	CcSEcCtD
Pergolide—Pain—Betamethasone—hematologic cancer	2.44e-05	5.3e-05	CcSEcCtD
Pergolide—Pain—Dexamethasone—hematologic cancer	2.44e-05	5.3e-05	CcSEcCtD
Pergolide—Visual impairment—Doxorubicin—hematologic cancer	2.44e-05	5.29e-05	CcSEcCtD
Pergolide—Tachycardia—Prednisone—hematologic cancer	2.42e-05	5.26e-05	CcSEcCtD
Pergolide—Alopecia—Epirubicin—hematologic cancer	2.42e-05	5.25e-05	CcSEcCtD
Pergolide—Nausea—Gemcitabine—hematologic cancer	2.41e-05	5.23e-05	CcSEcCtD
Pergolide—Vomiting—Cisplatin—hematologic cancer	2.41e-05	5.22e-05	CcSEcCtD
Pergolide—Hyperhidrosis—Prednisone—hematologic cancer	2.4e-05	5.21e-05	CcSEcCtD
Pergolide—Rash—Cisplatin—hematologic cancer	2.39e-05	5.18e-05	CcSEcCtD
Pergolide—Dermatitis—Cisplatin—hematologic cancer	2.38e-05	5.17e-05	CcSEcCtD
Pergolide—Diarrhoea—Etoposide—hematologic cancer	2.37e-05	5.15e-05	CcSEcCtD
Pergolide—Anorexia—Prednisone—hematologic cancer	2.37e-05	5.14e-05	CcSEcCtD
Pergolide—Eye disorder—Doxorubicin—hematologic cancer	2.36e-05	5.13e-05	CcSEcCtD
Pergolide—Ill-defined disorder—Methotrexate—hematologic cancer	2.36e-05	5.12e-05	CcSEcCtD
Pergolide—Tinnitus—Doxorubicin—hematologic cancer	2.36e-05	5.12e-05	CcSEcCtD
Pergolide—Anaemia—Methotrexate—hematologic cancer	2.35e-05	5.1e-05	CcSEcCtD
Pergolide—Feeling abnormal—Dexamethasone—hematologic cancer	2.35e-05	5.1e-05	CcSEcCtD
Pergolide—Feeling abnormal—Betamethasone—hematologic cancer	2.35e-05	5.1e-05	CcSEcCtD
Pergolide—Flatulence—Epirubicin—hematologic cancer	2.35e-05	5.09e-05	CcSEcCtD
Pergolide—Tension—Epirubicin—hematologic cancer	2.34e-05	5.07e-05	CcSEcCtD
Pergolide—Gastrointestinal pain—Betamethasone—hematologic cancer	2.33e-05	5.06e-05	CcSEcCtD
Pergolide—Gastrointestinal pain—Dexamethasone—hematologic cancer	2.33e-05	5.06e-05	CcSEcCtD
Pergolide—Dysgeusia—Epirubicin—hematologic cancer	2.33e-05	5.06e-05	CcSEcCtD
Pergolide—Nervousness—Epirubicin—hematologic cancer	2.31e-05	5.02e-05	CcSEcCtD
Pergolide—Back pain—Epirubicin—hematologic cancer	2.3e-05	5e-05	CcSEcCtD
Pergolide—Malaise—Methotrexate—hematologic cancer	2.29e-05	4.98e-05	CcSEcCtD
Pergolide—Dizziness—Etoposide—hematologic cancer	2.29e-05	4.98e-05	CcSEcCtD
Pergolide—Vertigo—Methotrexate—hematologic cancer	2.29e-05	4.96e-05	CcSEcCtD
Pergolide—Leukopenia—Methotrexate—hematologic cancer	2.28e-05	4.94e-05	CcSEcCtD
Pergolide—Chills—Doxorubicin—hematologic cancer	2.27e-05	4.93e-05	CcSEcCtD
Pergolide—Musculoskeletal discomfort—Prednisone—hematologic cancer	2.26e-05	4.91e-05	CcSEcCtD
Pergolide—Dizziness—Prednisolone—hematologic cancer	2.26e-05	4.91e-05	CcSEcCtD
Pergolide—Arrhythmia—Doxorubicin—hematologic cancer	2.26e-05	4.91e-05	CcSEcCtD
Pergolide—Asthenia—Triamcinolone—hematologic cancer	2.26e-05	4.9e-05	CcSEcCtD
Pergolide—Body temperature increased—Dexamethasone—hematologic cancer	2.25e-05	4.9e-05	CcSEcCtD
Pergolide—Abdominal pain—Dexamethasone—hematologic cancer	2.25e-05	4.9e-05	CcSEcCtD
Pergolide—Body temperature increased—Betamethasone—hematologic cancer	2.25e-05	4.9e-05	CcSEcCtD
Pergolide—Abdominal pain—Betamethasone—hematologic cancer	2.25e-05	4.9e-05	CcSEcCtD
Pergolide—Nausea—Cisplatin—hematologic cancer	2.25e-05	4.88e-05	CcSEcCtD
Pergolide—Insomnia—Prednisone—hematologic cancer	2.25e-05	4.88e-05	CcSEcCtD
Pergolide—Alopecia—Doxorubicin—hematologic cancer	2.24e-05	4.85e-05	CcSEcCtD
Pergolide—Paraesthesia—Prednisone—hematologic cancer	2.23e-05	4.84e-05	CcSEcCtD
Pergolide—Pruritus—Triamcinolone—hematologic cancer	2.22e-05	4.83e-05	CcSEcCtD
Pergolide—Cough—Methotrexate—hematologic cancer	2.22e-05	4.82e-05	CcSEcCtD
Pergolide—Ill-defined disorder—Epirubicin—hematologic cancer	2.21e-05	4.8e-05	CcSEcCtD
Pergolide—Convulsion—Methotrexate—hematologic cancer	2.2e-05	4.79e-05	CcSEcCtD
Pergolide—Vomiting—Etoposide—hematologic cancer	2.2e-05	4.78e-05	CcSEcCtD
Pergolide—Anaemia—Epirubicin—hematologic cancer	2.2e-05	4.78e-05	CcSEcCtD
Pergolide—Agitation—Epirubicin—hematologic cancer	2.19e-05	4.75e-05	CcSEcCtD
Pergolide—Dyspepsia—Prednisone—hematologic cancer	2.19e-05	4.75e-05	CcSEcCtD
Pergolide—Rash—Etoposide—hematologic cancer	2.18e-05	4.74e-05	CcSEcCtD
Pergolide—Dermatitis—Etoposide—hematologic cancer	2.18e-05	4.74e-05	CcSEcCtD
Pergolide—Headache—Etoposide—hematologic cancer	2.17e-05	4.71e-05	CcSEcCtD
Pergolide—Flatulence—Doxorubicin—hematologic cancer	2.17e-05	4.71e-05	CcSEcCtD
Pergolide—Myalgia—Methotrexate—hematologic cancer	2.17e-05	4.7e-05	CcSEcCtD
Pergolide—Arthralgia—Methotrexate—hematologic cancer	2.17e-05	4.7e-05	CcSEcCtD
Pergolide—Chest pain—Methotrexate—hematologic cancer	2.17e-05	4.7e-05	CcSEcCtD
Pergolide—Tension—Doxorubicin—hematologic cancer	2.16e-05	4.69e-05	CcSEcCtD
Pergolide—Decreased appetite—Prednisone—hematologic cancer	2.16e-05	4.69e-05	CcSEcCtD
Pergolide—Dysgeusia—Doxorubicin—hematologic cancer	2.16e-05	4.68e-05	CcSEcCtD
Pergolide—Rash—Prednisolone—hematologic cancer	2.16e-05	4.68e-05	CcSEcCtD
Pergolide—Dermatitis—Prednisolone—hematologic cancer	2.15e-05	4.68e-05	CcSEcCtD
Pergolide—Malaise—Epirubicin—hematologic cancer	2.15e-05	4.66e-05	CcSEcCtD
Pergolide—Headache—Prednisolone—hematologic cancer	2.14e-05	4.65e-05	CcSEcCtD
Pergolide—Discomfort—Methotrexate—hematologic cancer	2.14e-05	4.65e-05	CcSEcCtD
Pergolide—Nervousness—Doxorubicin—hematologic cancer	2.14e-05	4.64e-05	CcSEcCtD
Pergolide—Vertigo—Epirubicin—hematologic cancer	2.14e-05	4.64e-05	CcSEcCtD
Pergolide—Syncope—Epirubicin—hematologic cancer	2.13e-05	4.63e-05	CcSEcCtD
Pergolide—Leukopenia—Epirubicin—hematologic cancer	2.13e-05	4.63e-05	CcSEcCtD
Pergolide—Back pain—Doxorubicin—hematologic cancer	2.13e-05	4.63e-05	CcSEcCtD
Pergolide—Constipation—Prednisone—hematologic cancer	2.12e-05	4.61e-05	CcSEcCtD
Pergolide—Palpitations—Epirubicin—hematologic cancer	2.1e-05	4.57e-05	CcSEcCtD
Pergolide—Confusional state—Methotrexate—hematologic cancer	2.09e-05	4.54e-05	CcSEcCtD
Pergolide—Loss of consciousness—Epirubicin—hematologic cancer	2.09e-05	4.54e-05	CcSEcCtD
Pergolide—Dizziness—Triamcinolone—hematologic cancer	2.08e-05	4.51e-05	CcSEcCtD
Pergolide—Cough—Epirubicin—hematologic cancer	2.08e-05	4.51e-05	CcSEcCtD
Pergolide—Convulsion—Epirubicin—hematologic cancer	2.06e-05	4.48e-05	CcSEcCtD
Pergolide—Infection—Methotrexate—hematologic cancer	2.06e-05	4.48e-05	CcSEcCtD
Pergolide—Nausea—Etoposide—hematologic cancer	2.06e-05	4.47e-05	CcSEcCtD
Pergolide—Hypertension—Epirubicin—hematologic cancer	2.05e-05	4.46e-05	CcSEcCtD
Pergolide—Feeling abnormal—Prednisone—hematologic cancer	2.05e-05	4.44e-05	CcSEcCtD
Pergolide—Asthenia—Dexamethasone—hematologic cancer	2.05e-05	4.44e-05	CcSEcCtD
Pergolide—Asthenia—Betamethasone—hematologic cancer	2.05e-05	4.44e-05	CcSEcCtD
Pergolide—Ill-defined disorder—Doxorubicin—hematologic cancer	2.04e-05	4.44e-05	CcSEcCtD
Pergolide—Anaemia—Doxorubicin—hematologic cancer	2.04e-05	4.42e-05	CcSEcCtD
Pergolide—Thrombocytopenia—Methotrexate—hematologic cancer	2.03e-05	4.41e-05	CcSEcCtD
Pergolide—Gastrointestinal pain—Prednisone—hematologic cancer	2.03e-05	4.41e-05	CcSEcCtD
Pergolide—Nausea—Prednisolone—hematologic cancer	2.03e-05	4.41e-05	CcSEcCtD
Pergolide—Chest pain—Epirubicin—hematologic cancer	2.03e-05	4.4e-05	CcSEcCtD
Pergolide—Arthralgia—Epirubicin—hematologic cancer	2.03e-05	4.4e-05	CcSEcCtD
Pergolide—Myalgia—Epirubicin—hematologic cancer	2.03e-05	4.4e-05	CcSEcCtD
Pergolide—Agitation—Doxorubicin—hematologic cancer	2.02e-05	4.39e-05	CcSEcCtD
Pergolide—Anxiety—Epirubicin—hematologic cancer	2.02e-05	4.38e-05	CcSEcCtD
Pergolide—Pruritus—Betamethasone—hematologic cancer	2.02e-05	4.38e-05	CcSEcCtD
Pergolide—Pruritus—Dexamethasone—hematologic cancer	2.02e-05	4.38e-05	CcSEcCtD
Pergolide—Hyperhidrosis—Methotrexate—hematologic cancer	2.01e-05	4.36e-05	CcSEcCtD
Pergolide—Discomfort—Epirubicin—hematologic cancer	2e-05	4.35e-05	CcSEcCtD
Pergolide—Vomiting—Triamcinolone—hematologic cancer	2e-05	4.34e-05	CcSEcCtD
Pergolide—Malaise—Doxorubicin—hematologic cancer	1.99e-05	4.31e-05	CcSEcCtD
Pergolide—Rash—Triamcinolone—hematologic cancer	1.98e-05	4.3e-05	CcSEcCtD
Pergolide—Dry mouth—Epirubicin—hematologic cancer	1.98e-05	4.3e-05	CcSEcCtD
Pergolide—Dermatitis—Triamcinolone—hematologic cancer	1.98e-05	4.3e-05	CcSEcCtD
Pergolide—Vertigo—Doxorubicin—hematologic cancer	1.98e-05	4.3e-05	CcSEcCtD
Pergolide—Anorexia—Methotrexate—hematologic cancer	1.98e-05	4.3e-05	CcSEcCtD
Pergolide—Syncope—Doxorubicin—hematologic cancer	1.97e-05	4.29e-05	CcSEcCtD
Pergolide—Leukopenia—Doxorubicin—hematologic cancer	1.97e-05	4.28e-05	CcSEcCtD
Pergolide—Headache—Triamcinolone—hematologic cancer	1.97e-05	4.28e-05	CcSEcCtD
Pergolide—Body temperature increased—Prednisone—hematologic cancer	1.96e-05	4.26e-05	CcSEcCtD
Pergolide—Abdominal pain—Prednisone—hematologic cancer	1.96e-05	4.26e-05	CcSEcCtD
Pergolide—Confusional state—Epirubicin—hematologic cancer	1.96e-05	4.25e-05	CcSEcCtD
Pergolide—Diarrhoea—Dexamethasone—hematologic cancer	1.95e-05	4.24e-05	CcSEcCtD
Pergolide—Diarrhoea—Betamethasone—hematologic cancer	1.95e-05	4.24e-05	CcSEcCtD
Pergolide—Palpitations—Doxorubicin—hematologic cancer	1.95e-05	4.23e-05	CcSEcCtD
Pergolide—Oedema—Epirubicin—hematologic cancer	1.94e-05	4.22e-05	CcSEcCtD
Pergolide—Hypotension—Methotrexate—hematologic cancer	1.94e-05	4.21e-05	CcSEcCtD
Pergolide—Loss of consciousness—Doxorubicin—hematologic cancer	1.94e-05	4.2e-05	CcSEcCtD
Pergolide—Infection—Epirubicin—hematologic cancer	1.93e-05	4.19e-05	CcSEcCtD
Pergolide—Cough—Doxorubicin—hematologic cancer	1.92e-05	4.17e-05	CcSEcCtD
Pergolide—Shock—Epirubicin—hematologic cancer	1.91e-05	4.15e-05	CcSEcCtD
Pergolide—Convulsion—Doxorubicin—hematologic cancer	1.91e-05	4.14e-05	CcSEcCtD
Pergolide—Thrombocytopenia—Epirubicin—hematologic cancer	1.9e-05	4.13e-05	CcSEcCtD
Pergolide—Hypertension—Doxorubicin—hematologic cancer	1.9e-05	4.13e-05	CcSEcCtD
Pergolide—Tachycardia—Epirubicin—hematologic cancer	1.9e-05	4.12e-05	CcSEcCtD
Pergolide—Musculoskeletal discomfort—Methotrexate—hematologic cancer	1.89e-05	4.11e-05	CcSEcCtD
Pergolide—Dizziness—Betamethasone—hematologic cancer	1.89e-05	4.1e-05	CcSEcCtD
Pergolide—Dizziness—Dexamethasone—hematologic cancer	1.89e-05	4.1e-05	CcSEcCtD
Pergolide—Hyperhidrosis—Epirubicin—hematologic cancer	1.88e-05	4.08e-05	CcSEcCtD
Pergolide—Insomnia—Methotrexate—hematologic cancer	1.88e-05	4.08e-05	CcSEcCtD
Pergolide—Arthralgia—Doxorubicin—hematologic cancer	1.87e-05	4.07e-05	CcSEcCtD
Pergolide—Myalgia—Doxorubicin—hematologic cancer	1.87e-05	4.07e-05	CcSEcCtD
Pergolide—Chest pain—Doxorubicin—hematologic cancer	1.87e-05	4.07e-05	CcSEcCtD
Pergolide—Anxiety—Doxorubicin—hematologic cancer	1.87e-05	4.06e-05	CcSEcCtD
Pergolide—Nausea—Triamcinolone—hematologic cancer	1.87e-05	4.05e-05	CcSEcCtD
Pergolide—Paraesthesia—Methotrexate—hematologic cancer	1.86e-05	4.05e-05	CcSEcCtD
Pergolide—Discomfort—Doxorubicin—hematologic cancer	1.85e-05	4.02e-05	CcSEcCtD
Pergolide—Anorexia—Epirubicin—hematologic cancer	1.85e-05	4.02e-05	CcSEcCtD
Pergolide—Dyspnoea—Methotrexate—hematologic cancer	1.85e-05	4.02e-05	CcSEcCtD
Pergolide—Somnolence—Methotrexate—hematologic cancer	1.85e-05	4.01e-05	CcSEcCtD
Pergolide—Dry mouth—Doxorubicin—hematologic cancer	1.83e-05	3.98e-05	CcSEcCtD
Pergolide—Dyspepsia—Methotrexate—hematologic cancer	1.83e-05	3.97e-05	CcSEcCtD
Pergolide—Hypotension—Epirubicin—hematologic cancer	1.82e-05	3.94e-05	CcSEcCtD
Pergolide—Vomiting—Betamethasone—hematologic cancer	1.81e-05	3.94e-05	CcSEcCtD
Pergolide—Vomiting—Dexamethasone—hematologic cancer	1.81e-05	3.94e-05	CcSEcCtD
Pergolide—Confusional state—Doxorubicin—hematologic cancer	1.81e-05	3.94e-05	CcSEcCtD
Pergolide—Decreased appetite—Methotrexate—hematologic cancer	1.8e-05	3.92e-05	CcSEcCtD
Pergolide—Rash—Betamethasone—hematologic cancer	1.8e-05	3.9e-05	CcSEcCtD
Pergolide—Rash—Dexamethasone—hematologic cancer	1.8e-05	3.9e-05	CcSEcCtD
Pergolide—Oedema—Doxorubicin—hematologic cancer	1.8e-05	3.9e-05	CcSEcCtD
Pergolide—Dermatitis—Dexamethasone—hematologic cancer	1.8e-05	3.9e-05	CcSEcCtD
Pergolide—Dermatitis—Betamethasone—hematologic cancer	1.8e-05	3.9e-05	CcSEcCtD
Pergolide—Headache—Dexamethasone—hematologic cancer	1.79e-05	3.88e-05	CcSEcCtD
Pergolide—Headache—Betamethasone—hematologic cancer	1.79e-05	3.88e-05	CcSEcCtD
Pergolide—Infection—Doxorubicin—hematologic cancer	1.79e-05	3.88e-05	CcSEcCtD
Pergolide—Asthenia—Prednisone—hematologic cancer	1.78e-05	3.87e-05	CcSEcCtD
Pergolide—Pain—Methotrexate—hematologic cancer	1.78e-05	3.85e-05	CcSEcCtD
Pergolide—Musculoskeletal discomfort—Epirubicin—hematologic cancer	1.77e-05	3.84e-05	CcSEcCtD
Pergolide—Shock—Doxorubicin—hematologic cancer	1.77e-05	3.84e-05	CcSEcCtD
Pergolide—Thrombocytopenia—Doxorubicin—hematologic cancer	1.76e-05	3.82e-05	CcSEcCtD
Pergolide—Pruritus—Prednisone—hematologic cancer	1.76e-05	3.82e-05	CcSEcCtD
Pergolide—Insomnia—Epirubicin—hematologic cancer	1.76e-05	3.82e-05	CcSEcCtD
Pergolide—Tachycardia—Doxorubicin—hematologic cancer	1.75e-05	3.81e-05	CcSEcCtD
Pergolide—Paraesthesia—Epirubicin—hematologic cancer	1.74e-05	3.79e-05	CcSEcCtD
Pergolide—Hyperhidrosis—Doxorubicin—hematologic cancer	1.74e-05	3.77e-05	CcSEcCtD
Pergolide—Dyspnoea—Epirubicin—hematologic cancer	1.73e-05	3.76e-05	CcSEcCtD
Pergolide—Somnolence—Epirubicin—hematologic cancer	1.73e-05	3.75e-05	CcSEcCtD
Pergolide—Anorexia—Doxorubicin—hematologic cancer	1.71e-05	3.72e-05	CcSEcCtD
Pergolide—Feeling abnormal—Methotrexate—hematologic cancer	1.71e-05	3.71e-05	CcSEcCtD
Pergolide—Dyspepsia—Epirubicin—hematologic cancer	1.71e-05	3.71e-05	CcSEcCtD
Pergolide—Diarrhoea—Prednisone—hematologic cancer	1.7e-05	3.69e-05	CcSEcCtD
Pergolide—Gastrointestinal pain—Methotrexate—hematologic cancer	1.7e-05	3.69e-05	CcSEcCtD
Pergolide—Nausea—Betamethasone—hematologic cancer	1.69e-05	3.68e-05	CcSEcCtD
Pergolide—Nausea—Dexamethasone—hematologic cancer	1.69e-05	3.68e-05	CcSEcCtD
Pergolide—Decreased appetite—Epirubicin—hematologic cancer	1.69e-05	3.67e-05	CcSEcCtD
Pergolide—Hypotension—Doxorubicin—hematologic cancer	1.68e-05	3.65e-05	CcSEcCtD
Pergolide—Pain—Epirubicin—hematologic cancer	1.66e-05	3.61e-05	CcSEcCtD
Pergolide—Constipation—Epirubicin—hematologic cancer	1.66e-05	3.61e-05	CcSEcCtD
Pergolide—Dizziness—Prednisone—hematologic cancer	1.64e-05	3.57e-05	CcSEcCtD
Pergolide—Abdominal pain—Methotrexate—hematologic cancer	1.64e-05	3.56e-05	CcSEcCtD
Pergolide—Body temperature increased—Methotrexate—hematologic cancer	1.64e-05	3.56e-05	CcSEcCtD
Pergolide—Musculoskeletal discomfort—Doxorubicin—hematologic cancer	1.64e-05	3.56e-05	CcSEcCtD
Pergolide—Insomnia—Doxorubicin—hematologic cancer	1.63e-05	3.53e-05	CcSEcCtD
Pergolide—Paraesthesia—Doxorubicin—hematologic cancer	1.61e-05	3.5e-05	CcSEcCtD
Pergolide—Dyspnoea—Doxorubicin—hematologic cancer	1.6e-05	3.48e-05	CcSEcCtD
Pergolide—Feeling abnormal—Epirubicin—hematologic cancer	1.6e-05	3.48e-05	CcSEcCtD
Pergolide—Somnolence—Doxorubicin—hematologic cancer	1.6e-05	3.47e-05	CcSEcCtD
Pergolide—Gastrointestinal pain—Epirubicin—hematologic cancer	1.59e-05	3.45e-05	CcSEcCtD
Pergolide—Dyspepsia—Doxorubicin—hematologic cancer	1.58e-05	3.44e-05	CcSEcCtD
Pergolide—Vomiting—Prednisone—hematologic cancer	1.58e-05	3.43e-05	CcSEcCtD
Pergolide—Rash—Prednisone—hematologic cancer	1.57e-05	3.4e-05	CcSEcCtD
Pergolide—Dermatitis—Prednisone—hematologic cancer	1.56e-05	3.4e-05	CcSEcCtD
Pergolide—Decreased appetite—Doxorubicin—hematologic cancer	1.56e-05	3.39e-05	CcSEcCtD
Pergolide—Headache—Prednisone—hematologic cancer	1.56e-05	3.38e-05	CcSEcCtD
Pergolide—Pain—Doxorubicin—hematologic cancer	1.54e-05	3.34e-05	CcSEcCtD
Pergolide—Constipation—Doxorubicin—hematologic cancer	1.54e-05	3.34e-05	CcSEcCtD
Pergolide—Abdominal pain—Epirubicin—hematologic cancer	1.54e-05	3.33e-05	CcSEcCtD
Pergolide—Body temperature increased—Epirubicin—hematologic cancer	1.54e-05	3.33e-05	CcSEcCtD
Pergolide—Asthenia—Methotrexate—hematologic cancer	1.49e-05	3.23e-05	CcSEcCtD
Pergolide—Feeling abnormal—Doxorubicin—hematologic cancer	1.48e-05	3.22e-05	CcSEcCtD
Pergolide—Nausea—Prednisone—hematologic cancer	1.48e-05	3.2e-05	CcSEcCtD
Pergolide—Gastrointestinal pain—Doxorubicin—hematologic cancer	1.47e-05	3.19e-05	CcSEcCtD
Pergolide—Pruritus—Methotrexate—hematologic cancer	1.47e-05	3.19e-05	CcSEcCtD
Pergolide—Body temperature increased—Doxorubicin—hematologic cancer	1.42e-05	3.09e-05	CcSEcCtD
Pergolide—Abdominal pain—Doxorubicin—hematologic cancer	1.42e-05	3.09e-05	CcSEcCtD
Pergolide—Diarrhoea—Methotrexate—hematologic cancer	1.42e-05	3.08e-05	CcSEcCtD
Pergolide—Asthenia—Epirubicin—hematologic cancer	1.39e-05	3.03e-05	CcSEcCtD
Pergolide—Pruritus—Epirubicin—hematologic cancer	1.37e-05	2.98e-05	CcSEcCtD
Pergolide—Dizziness—Methotrexate—hematologic cancer	1.37e-05	2.98e-05	CcSEcCtD
Pergolide—Diarrhoea—Epirubicin—hematologic cancer	1.33e-05	2.89e-05	CcSEcCtD
Pergolide—Vomiting—Methotrexate—hematologic cancer	1.32e-05	2.87e-05	CcSEcCtD
Pergolide—Rash—Methotrexate—hematologic cancer	1.31e-05	2.84e-05	CcSEcCtD
Pergolide—Dermatitis—Methotrexate—hematologic cancer	1.31e-05	2.84e-05	CcSEcCtD
Pergolide—Headache—Methotrexate—hematologic cancer	1.3e-05	2.82e-05	CcSEcCtD
Pergolide—Asthenia—Doxorubicin—hematologic cancer	1.29e-05	2.8e-05	CcSEcCtD
Pergolide—Dizziness—Epirubicin—hematologic cancer	1.28e-05	2.79e-05	CcSEcCtD
Pergolide—Pruritus—Doxorubicin—hematologic cancer	1.27e-05	2.76e-05	CcSEcCtD
Pergolide—Vomiting—Epirubicin—hematologic cancer	1.24e-05	2.68e-05	CcSEcCtD
Pergolide—Nausea—Methotrexate—hematologic cancer	1.23e-05	2.68e-05	CcSEcCtD
Pergolide—Diarrhoea—Doxorubicin—hematologic cancer	1.23e-05	2.67e-05	CcSEcCtD
Pergolide—Rash—Epirubicin—hematologic cancer	1.22e-05	2.66e-05	CcSEcCtD
Pergolide—Dermatitis—Epirubicin—hematologic cancer	1.22e-05	2.66e-05	CcSEcCtD
Pergolide—Headache—Epirubicin—hematologic cancer	1.22e-05	2.64e-05	CcSEcCtD
Pergolide—Dizziness—Doxorubicin—hematologic cancer	1.19e-05	2.58e-05	CcSEcCtD
Pergolide—Nausea—Epirubicin—hematologic cancer	1.15e-05	2.51e-05	CcSEcCtD
Pergolide—Vomiting—Doxorubicin—hematologic cancer	1.14e-05	2.48e-05	CcSEcCtD
Pergolide—Rash—Doxorubicin—hematologic cancer	1.13e-05	2.46e-05	CcSEcCtD
Pergolide—Dermatitis—Doxorubicin—hematologic cancer	1.13e-05	2.46e-05	CcSEcCtD
Pergolide—Headache—Doxorubicin—hematologic cancer	1.13e-05	2.45e-05	CcSEcCtD
Pergolide—Nausea—Doxorubicin—hematologic cancer	1.07e-05	2.32e-05	CcSEcCtD
Pergolide—ADRA1D—Signaling Pathways—MYC—hematologic cancer	2.94e-06	1.86e-05	CbGpPWpGaD
Pergolide—ADRA1B—Signaling Pathways—PTEN—hematologic cancer	2.94e-06	1.86e-05	CbGpPWpGaD
Pergolide—ADRA1D—Signaling Pathways—TGFB1—hematologic cancer	2.94e-06	1.86e-05	CbGpPWpGaD
Pergolide—DRD3—Signaling Pathways—TGFB1—hematologic cancer	2.94e-06	1.86e-05	CbGpPWpGaD
Pergolide—HTR2C—Signaling Pathways—EP300—hematologic cancer	2.93e-06	1.85e-05	CbGpPWpGaD
Pergolide—HTR2B—Signaling Pathways—KRAS—hematologic cancer	2.92e-06	1.85e-05	CbGpPWpGaD
Pergolide—ADRA2C—Signaling Pathways—MAPK8—hematologic cancer	2.92e-06	1.85e-05	CbGpPWpGaD
Pergolide—HTR1D—Signaling Pathways—PIK3CA—hematologic cancer	2.92e-06	1.85e-05	CbGpPWpGaD
Pergolide—ADRA2C—Signaling by GPCR—AKT1—hematologic cancer	2.92e-06	1.84e-05	CbGpPWpGaD
Pergolide—DRD2—GPCR downstream signaling—AKT1—hematologic cancer	2.91e-06	1.84e-05	CbGpPWpGaD
Pergolide—ADRA2A—Metabolism—PTEN—hematologic cancer	2.9e-06	1.83e-05	CbGpPWpGaD
Pergolide—ADRA2A—Signaling by GPCR—PIK3CA—hematologic cancer	2.9e-06	1.83e-05	CbGpPWpGaD
Pergolide—HTR2A—Signaling Pathways—CDKN1B—hematologic cancer	2.9e-06	1.83e-05	CbGpPWpGaD
Pergolide—ADRA2B—Signaling Pathways—VEGFA—hematologic cancer	2.89e-06	1.83e-05	CbGpPWpGaD
Pergolide—ADRA2A—Signaling Pathways—MDM2—hematologic cancer	2.89e-06	1.82e-05	CbGpPWpGaD
Pergolide—ADRA1A—Signaling by GPCR—HRAS—hematologic cancer	2.89e-06	1.82e-05	CbGpPWpGaD
Pergolide—DRD2—Signaling Pathways—CASP3—hematologic cancer	2.89e-06	1.82e-05	CbGpPWpGaD
Pergolide—DRD2—Signaling Pathways—IL2—hematologic cancer	2.88e-06	1.82e-05	CbGpPWpGaD
Pergolide—ADRA1B—Signaling Pathways—MAPK8—hematologic cancer	2.88e-06	1.82e-05	CbGpPWpGaD
Pergolide—ADRA1B—Signaling by GPCR—AKT1—hematologic cancer	2.87e-06	1.81e-05	CbGpPWpGaD
Pergolide—DRD2—Signaling by GPCR—IL6—hematologic cancer	2.87e-06	1.81e-05	CbGpPWpGaD
Pergolide—HTR2A—GPCR downstream signaling—AKT1—hematologic cancer	2.87e-06	1.81e-05	CbGpPWpGaD
Pergolide—HTR1A—Signaling Pathways—SRC—hematologic cancer	2.86e-06	1.81e-05	CbGpPWpGaD
Pergolide—ADRA2B—Signaling Pathways—STAT3—hematologic cancer	2.86e-06	1.81e-05	CbGpPWpGaD
Pergolide—HTR1B—Signaling Pathways—PIK3CA—hematologic cancer	2.86e-06	1.81e-05	CbGpPWpGaD
Pergolide—CYP2D6—Metabolism—PIK3CG—hematologic cancer	2.86e-06	1.81e-05	CbGpPWpGaD
Pergolide—ADRA2B—Signaling Pathways—NRAS—hematologic cancer	2.85e-06	1.8e-05	CbGpPWpGaD
Pergolide—ADRA2C—Signaling Pathways—EP300—hematologic cancer	2.85e-06	1.8e-05	CbGpPWpGaD
Pergolide—HTR2C—Signaling Pathways—SRC—hematologic cancer	2.85e-06	1.8e-05	CbGpPWpGaD
Pergolide—HTR2A—Signaling Pathways—CASP3—hematologic cancer	2.84e-06	1.79e-05	CbGpPWpGaD
Pergolide—ADRA1A—Signaling Pathways—CDKN1B—hematologic cancer	2.84e-06	1.79e-05	CbGpPWpGaD
Pergolide—HTR2A—Signaling Pathways—IL2—hematologic cancer	2.84e-06	1.79e-05	CbGpPWpGaD
Pergolide—HTR1D—Signaling Pathways—TP53—hematologic cancer	2.83e-06	1.79e-05	CbGpPWpGaD
Pergolide—HTR2A—Signaling by GPCR—IL6—hematologic cancer	2.82e-06	1.78e-05	CbGpPWpGaD
Pergolide—DRD4—Signaling Pathways—PIK3CA—hematologic cancer	2.81e-06	1.78e-05	CbGpPWpGaD
Pergolide—DRD2—Signaling Pathways—CCND1—hematologic cancer	2.81e-06	1.78e-05	CbGpPWpGaD
Pergolide—ADRA2A—Signaling Pathways—MTOR—hematologic cancer	2.81e-06	1.77e-05	CbGpPWpGaD
Pergolide—ADRA2A—Signaling Pathways—PIK3CB—hematologic cancer	2.81e-06	1.77e-05	CbGpPWpGaD
Pergolide—ADRA1A—GPCR downstream signaling—AKT1—hematologic cancer	2.81e-06	1.77e-05	CbGpPWpGaD
Pergolide—ADRA1B—Signaling Pathways—EP300—hematologic cancer	2.8e-06	1.77e-05	CbGpPWpGaD
Pergolide—DRD2—Signaling Pathways—JUN—hematologic cancer	2.8e-06	1.77e-05	CbGpPWpGaD
Pergolide—HTR1A—Signaling Pathways—VEGFA—hematologic cancer	2.79e-06	1.76e-05	CbGpPWpGaD
Pergolide—ADRA1A—Signaling Pathways—CASP3—hematologic cancer	2.78e-06	1.76e-05	CbGpPWpGaD
Pergolide—ADRA1A—Signaling Pathways—IL2—hematologic cancer	2.78e-06	1.75e-05	CbGpPWpGaD
Pergolide—HTR2C—Signaling Pathways—VEGFA—hematologic cancer	2.78e-06	1.75e-05	CbGpPWpGaD
Pergolide—ADRA2C—Signaling Pathways—SRC—hematologic cancer	2.77e-06	1.75e-05	CbGpPWpGaD
Pergolide—ADRA2A—Metabolism—EP300—hematologic cancer	2.77e-06	1.75e-05	CbGpPWpGaD
Pergolide—HTR1B—Signaling Pathways—TP53—hematologic cancer	2.77e-06	1.75e-05	CbGpPWpGaD
Pergolide—HTR2A—Signaling Pathways—CCND1—hematologic cancer	2.76e-06	1.75e-05	CbGpPWpGaD
Pergolide—ADRA1A—Signaling by GPCR—IL6—hematologic cancer	2.76e-06	1.75e-05	CbGpPWpGaD
Pergolide—HTR1A—Signaling Pathways—STAT3—hematologic cancer	2.76e-06	1.75e-05	CbGpPWpGaD
Pergolide—HTR2A—Signaling Pathways—JUN—hematologic cancer	2.76e-06	1.74e-05	CbGpPWpGaD
Pergolide—DRD1—Signaling Pathways—KRAS—hematologic cancer	2.76e-06	1.74e-05	CbGpPWpGaD
Pergolide—HTR1A—Signaling Pathways—NRAS—hematologic cancer	2.76e-06	1.74e-05	CbGpPWpGaD
Pergolide—HTR2C—Signaling Pathways—STAT3—hematologic cancer	2.75e-06	1.74e-05	CbGpPWpGaD
Pergolide—HTR2C—Signaling Pathways—NRAS—hematologic cancer	2.74e-06	1.73e-05	CbGpPWpGaD
Pergolide—CYP3A4—Metabolism—GSTP1—hematologic cancer	2.74e-06	1.73e-05	CbGpPWpGaD
Pergolide—ADRA2B—Signaling Pathways—MAPK3—hematologic cancer	2.73e-06	1.73e-05	CbGpPWpGaD
Pergolide—ADRA1B—Signaling Pathways—SRC—hematologic cancer	2.73e-06	1.72e-05	CbGpPWpGaD
Pergolide—DRD4—Signaling Pathways—TP53—hematologic cancer	2.72e-06	1.72e-05	CbGpPWpGaD
Pergolide—ADRA1D—Signaling Pathways—KRAS—hematologic cancer	2.72e-06	1.72e-05	CbGpPWpGaD
Pergolide—DRD3—Signaling Pathways—KRAS—hematologic cancer	2.72e-06	1.72e-05	CbGpPWpGaD
Pergolide—DRD2—Signaling Pathways—CDKN1A—hematologic cancer	2.72e-06	1.72e-05	CbGpPWpGaD
Pergolide—DRD2—Signaling Pathways—PTEN—hematologic cancer	2.71e-06	1.71e-05	CbGpPWpGaD
Pergolide—ADRA1A—Signaling Pathways—CCND1—hematologic cancer	2.71e-06	1.71e-05	CbGpPWpGaD
Pergolide—HTR1D—Signaling Pathways—HRAS—hematologic cancer	2.7e-06	1.71e-05	CbGpPWpGaD
Pergolide—ADRA1A—Signaling Pathways—JUN—hematologic cancer	2.7e-06	1.71e-05	CbGpPWpGaD
Pergolide—ADRA2C—Signaling Pathways—VEGFA—hematologic cancer	2.7e-06	1.71e-05	CbGpPWpGaD
Pergolide—HTR2B—Signaling Pathways—PIK3CA—hematologic cancer	2.69e-06	1.7e-05	CbGpPWpGaD
Pergolide—ADRA2A—Signaling by GPCR—HRAS—hematologic cancer	2.68e-06	1.69e-05	CbGpPWpGaD
Pergolide—HTR2A—Signaling Pathways—CDKN1A—hematologic cancer	2.67e-06	1.69e-05	CbGpPWpGaD
Pergolide—ADRA2C—Signaling Pathways—STAT3—hematologic cancer	2.67e-06	1.69e-05	CbGpPWpGaD
Pergolide—HTR2A—Signaling Pathways—PTEN—hematologic cancer	2.67e-06	1.69e-05	CbGpPWpGaD
Pergolide—ADRA2C—Signaling Pathways—NRAS—hematologic cancer	2.67e-06	1.68e-05	CbGpPWpGaD
Pergolide—ADRA2B—Signaling Pathways—MYC—hematologic cancer	2.66e-06	1.68e-05	CbGpPWpGaD
Pergolide—ADRA1B—Signaling Pathways—VEGFA—hematologic cancer	2.66e-06	1.68e-05	CbGpPWpGaD
Pergolide—DRD2—Signaling Pathways—MAPK8—hematologic cancer	2.65e-06	1.68e-05	CbGpPWpGaD
Pergolide—ADRA2B—Signaling Pathways—TGFB1—hematologic cancer	2.65e-06	1.68e-05	CbGpPWpGaD
Pergolide—CYP2D6—Metabolism—CREBBP—hematologic cancer	2.65e-06	1.67e-05	CbGpPWpGaD
Pergolide—HTR1B—Signaling Pathways—HRAS—hematologic cancer	2.65e-06	1.67e-05	CbGpPWpGaD
Pergolide—DRD2—Signaling by GPCR—AKT1—hematologic cancer	2.65e-06	1.67e-05	CbGpPWpGaD
Pergolide—HTR1A—Signaling Pathways—MAPK3—hematologic cancer	2.64e-06	1.67e-05	CbGpPWpGaD
Pergolide—ADRA2A—Signaling Pathways—CDKN1B—hematologic cancer	2.64e-06	1.67e-05	CbGpPWpGaD
Pergolide—ADRA1B—Signaling Pathways—STAT3—hematologic cancer	2.63e-06	1.66e-05	CbGpPWpGaD
Pergolide—HTR2C—Signaling Pathways—MAPK3—hematologic cancer	2.63e-06	1.66e-05	CbGpPWpGaD
Pergolide—ADRA1B—Signaling Pathways—NRAS—hematologic cancer	2.62e-06	1.66e-05	CbGpPWpGaD
Pergolide—ADRA1A—Signaling Pathways—CDKN1A—hematologic cancer	2.62e-06	1.65e-05	CbGpPWpGaD
Pergolide—ADRA1A—Signaling Pathways—PTEN—hematologic cancer	2.61e-06	1.65e-05	CbGpPWpGaD
Pergolide—HTR2A—Signaling Pathways—MAPK8—hematologic cancer	2.61e-06	1.65e-05	CbGpPWpGaD
Pergolide—ADRA2A—GPCR downstream signaling—AKT1—hematologic cancer	2.61e-06	1.65e-05	CbGpPWpGaD
Pergolide—DRD4—Signaling Pathways—HRAS—hematologic cancer	2.6e-06	1.65e-05	CbGpPWpGaD
Pergolide—HTR2A—Signaling by GPCR—AKT1—hematologic cancer	2.6e-06	1.64e-05	CbGpPWpGaD
Pergolide—HTR2B—Signaling Pathways—TP53—hematologic cancer	2.6e-06	1.64e-05	CbGpPWpGaD
Pergolide—CYP3A4—Metabolism—ABCB1—hematologic cancer	2.59e-06	1.64e-05	CbGpPWpGaD
Pergolide—HTR1D—Signaling Pathways—IL6—hematologic cancer	2.59e-06	1.63e-05	CbGpPWpGaD
Pergolide—DRD2—Signaling Pathways—EP300—hematologic cancer	2.59e-06	1.63e-05	CbGpPWpGaD
Pergolide—ADRA2A—Signaling Pathways—CASP3—hematologic cancer	2.58e-06	1.63e-05	CbGpPWpGaD
Pergolide—ADRA2A—Signaling Pathways—IL2—hematologic cancer	2.58e-06	1.63e-05	CbGpPWpGaD
Pergolide—ADRA2A—Signaling by GPCR—IL6—hematologic cancer	2.57e-06	1.62e-05	CbGpPWpGaD
Pergolide—HTR1A—Signaling Pathways—MYC—hematologic cancer	2.57e-06	1.62e-05	CbGpPWpGaD
Pergolide—HTR1A—Signaling Pathways—TGFB1—hematologic cancer	2.56e-06	1.62e-05	CbGpPWpGaD
Pergolide—ADRA1A—Signaling Pathways—MAPK8—hematologic cancer	2.56e-06	1.61e-05	CbGpPWpGaD
Pergolide—ADRA2C—Signaling Pathways—MAPK3—hematologic cancer	2.55e-06	1.61e-05	CbGpPWpGaD
Pergolide—HTR2C—Signaling Pathways—MYC—hematologic cancer	2.55e-06	1.61e-05	CbGpPWpGaD
Pergolide—ADRA1A—Signaling by GPCR—AKT1—hematologic cancer	2.55e-06	1.61e-05	CbGpPWpGaD
Pergolide—HTR2C—Signaling Pathways—TGFB1—hematologic cancer	2.55e-06	1.61e-05	CbGpPWpGaD
Pergolide—HTR2A—Signaling Pathways—EP300—hematologic cancer	2.54e-06	1.61e-05	CbGpPWpGaD
Pergolide—DRD1—Signaling Pathways—PIK3CA—hematologic cancer	2.53e-06	1.6e-05	CbGpPWpGaD
Pergolide—HTR1B—Signaling Pathways—IL6—hematologic cancer	2.53e-06	1.6e-05	CbGpPWpGaD
Pergolide—ADRA2C—Metabolism—PIK3CA—hematologic cancer	2.52e-06	1.59e-05	CbGpPWpGaD
Pergolide—CYP3A4—Metabolism—NCOR1—hematologic cancer	2.52e-06	1.59e-05	CbGpPWpGaD
Pergolide—CYP3A4—Metabolism—GSTM1—hematologic cancer	2.52e-06	1.59e-05	CbGpPWpGaD
Pergolide—ADRA2A—Signaling Pathways—CCND1—hematologic cancer	2.51e-06	1.59e-05	CbGpPWpGaD
Pergolide—DRD2—Signaling Pathways—SRC—hematologic cancer	2.51e-06	1.59e-05	CbGpPWpGaD
Pergolide—ADRA1B—Signaling Pathways—MAPK3—hematologic cancer	2.51e-06	1.59e-05	CbGpPWpGaD
Pergolide—CYP2D6—Metabolism—PIK3CD—hematologic cancer	2.51e-06	1.59e-05	CbGpPWpGaD
Pergolide—ADRA2A—Signaling Pathways—JUN—hematologic cancer	2.51e-06	1.59e-05	CbGpPWpGaD
Pergolide—ADRA1D—Signaling Pathways—PIK3CA—hematologic cancer	2.5e-06	1.58e-05	CbGpPWpGaD
Pergolide—DRD3—Signaling Pathways—PIK3CA—hematologic cancer	2.5e-06	1.58e-05	CbGpPWpGaD
Pergolide—DRD4—Signaling Pathways—IL6—hematologic cancer	2.49e-06	1.57e-05	CbGpPWpGaD
Pergolide—ADRA1A—Signaling Pathways—EP300—hematologic cancer	2.49e-06	1.57e-05	CbGpPWpGaD
Pergolide—HTR2B—Signaling Pathways—HRAS—hematologic cancer	2.49e-06	1.57e-05	CbGpPWpGaD
Pergolide—ADRA2C—Signaling Pathways—MYC—hematologic cancer	2.48e-06	1.57e-05	CbGpPWpGaD
Pergolide—CYP2D6—Metabolism—ALB—hematologic cancer	2.48e-06	1.57e-05	CbGpPWpGaD
Pergolide—ADRA2C—Signaling Pathways—TGFB1—hematologic cancer	2.48e-06	1.57e-05	CbGpPWpGaD
Pergolide—HTR2A—Signaling Pathways—SRC—hematologic cancer	2.47e-06	1.56e-05	CbGpPWpGaD
Pergolide—ADRA2B—Signaling Pathways—KRAS—hematologic cancer	2.46e-06	1.55e-05	CbGpPWpGaD
Pergolide—DRD1—Signaling Pathways—TP53—hematologic cancer	2.45e-06	1.55e-05	CbGpPWpGaD
Pergolide—DRD2—Signaling Pathways—VEGFA—hematologic cancer	2.45e-06	1.55e-05	CbGpPWpGaD
Pergolide—ADRA1B—Signaling Pathways—MYC—hematologic cancer	2.44e-06	1.54e-05	CbGpPWpGaD
Pergolide—ADRA1B—Signaling Pathways—TGFB1—hematologic cancer	2.44e-06	1.54e-05	CbGpPWpGaD
Pergolide—ADRA2A—Signaling Pathways—CDKN1A—hematologic cancer	2.43e-06	1.54e-05	CbGpPWpGaD
Pergolide—ADRA2A—Signaling Pathways—PTEN—hematologic cancer	2.43e-06	1.53e-05	CbGpPWpGaD
Pergolide—DRD2—Signaling Pathways—STAT3—hematologic cancer	2.42e-06	1.53e-05	CbGpPWpGaD
Pergolide—ADRA1A—Signaling Pathways—SRC—hematologic cancer	2.42e-06	1.53e-05	CbGpPWpGaD
Pergolide—DRD2—Signaling Pathways—NRAS—hematologic cancer	2.42e-06	1.53e-05	CbGpPWpGaD
Pergolide—ADRA1D—Signaling Pathways—TP53—hematologic cancer	2.42e-06	1.53e-05	CbGpPWpGaD
Pergolide—DRD3—Signaling Pathways—TP53—hematologic cancer	2.42e-06	1.53e-05	CbGpPWpGaD
Pergolide—HTR2A—Signaling Pathways—VEGFA—hematologic cancer	2.41e-06	1.52e-05	CbGpPWpGaD
Pergolide—HTR1D—Signaling Pathways—AKT1—hematologic cancer	2.39e-06	1.51e-05	CbGpPWpGaD
Pergolide—HTR2A—Signaling Pathways—STAT3—hematologic cancer	2.39e-06	1.51e-05	CbGpPWpGaD
Pergolide—HTR2A—Signaling Pathways—NRAS—hematologic cancer	2.38e-06	1.5e-05	CbGpPWpGaD
Pergolide—HTR2B—Signaling Pathways—IL6—hematologic cancer	2.38e-06	1.5e-05	CbGpPWpGaD
Pergolide—ADRA2A—Signaling Pathways—MAPK8—hematologic cancer	2.37e-06	1.5e-05	CbGpPWpGaD
Pergolide—CYP2D6—Metabolism—PIK3R1—hematologic cancer	2.37e-06	1.5e-05	CbGpPWpGaD
Pergolide—HTR1A—Signaling Pathways—KRAS—hematologic cancer	2.37e-06	1.5e-05	CbGpPWpGaD
Pergolide—ADRA2A—Signaling by GPCR—AKT1—hematologic cancer	2.37e-06	1.5e-05	CbGpPWpGaD
Pergolide—ADRA1A—Signaling Pathways—VEGFA—hematologic cancer	2.36e-06	1.49e-05	CbGpPWpGaD
Pergolide—HTR2C—Signaling Pathways—KRAS—hematologic cancer	2.36e-06	1.49e-05	CbGpPWpGaD
Pergolide—DRD1—Signaling Pathways—HRAS—hematologic cancer	2.34e-06	1.48e-05	CbGpPWpGaD
Pergolide—ADRA1A—Signaling Pathways—STAT3—hematologic cancer	2.34e-06	1.48e-05	CbGpPWpGaD
Pergolide—HTR1B—Signaling Pathways—AKT1—hematologic cancer	2.34e-06	1.48e-05	CbGpPWpGaD
Pergolide—ADRA1A—Signaling Pathways—NRAS—hematologic cancer	2.33e-06	1.47e-05	CbGpPWpGaD
Pergolide—DRD2—Signaling Pathways—MAPK3—hematologic cancer	2.32e-06	1.46e-05	CbGpPWpGaD
Pergolide—ADRA2A—Signaling Pathways—EP300—hematologic cancer	2.31e-06	1.46e-05	CbGpPWpGaD
Pergolide—DRD3—Signaling Pathways—HRAS—hematologic cancer	2.31e-06	1.46e-05	CbGpPWpGaD
Pergolide—ADRA1D—Signaling Pathways—HRAS—hematologic cancer	2.31e-06	1.46e-05	CbGpPWpGaD
Pergolide—DRD4—Signaling Pathways—AKT1—hematologic cancer	2.3e-06	1.45e-05	CbGpPWpGaD
Pergolide—ADRA2C—Signaling Pathways—KRAS—hematologic cancer	2.29e-06	1.45e-05	CbGpPWpGaD
Pergolide—HTR2A—Signaling Pathways—MAPK3—hematologic cancer	2.28e-06	1.44e-05	CbGpPWpGaD
Pergolide—ADRA1B—Signaling Pathways—KRAS—hematologic cancer	2.26e-06	1.43e-05	CbGpPWpGaD
Pergolide—ADRA2B—Signaling Pathways—PIK3CA—hematologic cancer	2.26e-06	1.43e-05	CbGpPWpGaD
Pergolide—DRD2—Signaling Pathways—MYC—hematologic cancer	2.25e-06	1.42e-05	CbGpPWpGaD
Pergolide—ADRA2A—Signaling Pathways—SRC—hematologic cancer	2.25e-06	1.42e-05	CbGpPWpGaD
Pergolide—DRD2—Signaling Pathways—TGFB1—hematologic cancer	2.25e-06	1.42e-05	CbGpPWpGaD
Pergolide—DRD1—Signaling Pathways—IL6—hematologic cancer	2.24e-06	1.42e-05	CbGpPWpGaD
Pergolide—ADRA1A—Signaling Pathways—MAPK3—hematologic cancer	2.23e-06	1.41e-05	CbGpPWpGaD
Pergolide—CYP3A4—Metabolism—MTHFR—hematologic cancer	2.22e-06	1.4e-05	CbGpPWpGaD
Pergolide—HTR2A—Signaling Pathways—MYC—hematologic cancer	2.22e-06	1.4e-05	CbGpPWpGaD
Pergolide—DRD3—Signaling Pathways—IL6—hematologic cancer	2.21e-06	1.4e-05	CbGpPWpGaD
Pergolide—ADRA1D—Signaling Pathways—IL6—hematologic cancer	2.21e-06	1.4e-05	CbGpPWpGaD
Pergolide—HTR2A—Signaling Pathways—TGFB1—hematologic cancer	2.21e-06	1.4e-05	CbGpPWpGaD
Pergolide—HTR2B—Signaling Pathways—AKT1—hematologic cancer	2.19e-06	1.39e-05	CbGpPWpGaD
Pergolide—ADRA2A—Signaling Pathways—VEGFA—hematologic cancer	2.19e-06	1.39e-05	CbGpPWpGaD
Pergolide—CYP2D6—Metabolism—PIK3CB—hematologic cancer	2.19e-06	1.38e-05	CbGpPWpGaD
Pergolide—ADRA2B—Signaling Pathways—TP53—hematologic cancer	2.18e-06	1.38e-05	CbGpPWpGaD
Pergolide—HTR1A—Signaling Pathways—PIK3CA—hematologic cancer	2.18e-06	1.38e-05	CbGpPWpGaD
Pergolide—ADRA1A—Signaling Pathways—MYC—hematologic cancer	2.17e-06	1.37e-05	CbGpPWpGaD
Pergolide—ADRA2A—Signaling Pathways—STAT3—hematologic cancer	2.17e-06	1.37e-05	CbGpPWpGaD
Pergolide—HTR2C—Signaling Pathways—PIK3CA—hematologic cancer	2.17e-06	1.37e-05	CbGpPWpGaD
Pergolide—ADRA1A—Signaling Pathways—TGFB1—hematologic cancer	2.17e-06	1.37e-05	CbGpPWpGaD
Pergolide—ADRA2A—Signaling Pathways—NRAS—hematologic cancer	2.17e-06	1.37e-05	CbGpPWpGaD
Pergolide—ADRA2C—Signaling Pathways—PIK3CA—hematologic cancer	2.11e-06	1.33e-05	CbGpPWpGaD
Pergolide—HTR1A—Signaling Pathways—TP53—hematologic cancer	2.11e-06	1.33e-05	CbGpPWpGaD
Pergolide—HTR2C—Signaling Pathways—TP53—hematologic cancer	2.1e-06	1.32e-05	CbGpPWpGaD
Pergolide—ADRA2B—Signaling Pathways—HRAS—hematologic cancer	2.09e-06	1.32e-05	CbGpPWpGaD
Pergolide—DRD2—Signaling Pathways—KRAS—hematologic cancer	2.08e-06	1.32e-05	CbGpPWpGaD
Pergolide—ADRA1B—Signaling Pathways—PIK3CA—hematologic cancer	2.07e-06	1.31e-05	CbGpPWpGaD
Pergolide—ADRA2A—Signaling Pathways—MAPK3—hematologic cancer	2.07e-06	1.31e-05	CbGpPWpGaD
Pergolide—DRD1—Signaling Pathways—AKT1—hematologic cancer	2.07e-06	1.31e-05	CbGpPWpGaD
Pergolide—ADRA2C—Metabolism—AKT1—hematologic cancer	2.06e-06	1.3e-05	CbGpPWpGaD
Pergolide—HTR2A—Signaling Pathways—KRAS—hematologic cancer	2.05e-06	1.29e-05	CbGpPWpGaD
Pergolide—ADRA2A—Metabolism—PIK3CA—hematologic cancer	2.05e-06	1.29e-05	CbGpPWpGaD
Pergolide—ADRA1D—Signaling Pathways—AKT1—hematologic cancer	2.04e-06	1.29e-05	CbGpPWpGaD
Pergolide—DRD3—Signaling Pathways—AKT1—hematologic cancer	2.04e-06	1.29e-05	CbGpPWpGaD
Pergolide—ADRA2C—Signaling Pathways—TP53—hematologic cancer	2.04e-06	1.29e-05	CbGpPWpGaD
Pergolide—ADRA2A—Signaling Pathways—MYC—hematologic cancer	2.02e-06	1.27e-05	CbGpPWpGaD
Pergolide—HTR1A—Signaling Pathways—HRAS—hematologic cancer	2.02e-06	1.27e-05	CbGpPWpGaD
Pergolide—ADRA2A—Signaling Pathways—TGFB1—hematologic cancer	2.01e-06	1.27e-05	CbGpPWpGaD
Pergolide—ADRA1B—Signaling Pathways—TP53—hematologic cancer	2.01e-06	1.27e-05	CbGpPWpGaD
Pergolide—ADRA1A—Signaling Pathways—KRAS—hematologic cancer	2.01e-06	1.27e-05	CbGpPWpGaD
Pergolide—HTR2C—Signaling Pathways—HRAS—hematologic cancer	2.01e-06	1.27e-05	CbGpPWpGaD
Pergolide—ADRA2B—Signaling Pathways—IL6—hematologic cancer	2e-06	1.26e-05	CbGpPWpGaD
Pergolide—ADRA2C—Signaling Pathways—HRAS—hematologic cancer	1.95e-06	1.23e-05	CbGpPWpGaD
Pergolide—HTR1A—Signaling Pathways—IL6—hematologic cancer	1.93e-06	1.22e-05	CbGpPWpGaD
Pergolide—ADRA1B—Signaling Pathways—HRAS—hematologic cancer	1.92e-06	1.21e-05	CbGpPWpGaD
Pergolide—HTR2C—Signaling Pathways—IL6—hematologic cancer	1.92e-06	1.21e-05	CbGpPWpGaD
Pergolide—DRD2—Signaling Pathways—PIK3CA—hematologic cancer	1.91e-06	1.21e-05	CbGpPWpGaD
Pergolide—CYP2D6—Metabolism—PTEN—hematologic cancer	1.89e-06	1.2e-05	CbGpPWpGaD
Pergolide—HTR2A—Signaling Pathways—PIK3CA—hematologic cancer	1.88e-06	1.19e-05	CbGpPWpGaD
Pergolide—CYP3A4—Metabolism—PIK3CG—hematologic cancer	1.87e-06	1.18e-05	CbGpPWpGaD
Pergolide—ADRA2C—Signaling Pathways—IL6—hematologic cancer	1.87e-06	1.18e-05	CbGpPWpGaD
Pergolide—ADRA2A—Signaling Pathways—KRAS—hematologic cancer	1.86e-06	1.18e-05	CbGpPWpGaD
Pergolide—DRD2—Signaling Pathways—TP53—hematologic cancer	1.85e-06	1.17e-05	CbGpPWpGaD
Pergolide—ADRA2B—Signaling Pathways—AKT1—hematologic cancer	1.84e-06	1.16e-05	CbGpPWpGaD
Pergolide—ADRA1A—Signaling Pathways—PIK3CA—hematologic cancer	1.84e-06	1.16e-05	CbGpPWpGaD
Pergolide—ADRA1B—Signaling Pathways—IL6—hematologic cancer	1.84e-06	1.16e-05	CbGpPWpGaD
Pergolide—HTR2A—Signaling Pathways—TP53—hematologic cancer	1.82e-06	1.15e-05	CbGpPWpGaD
Pergolide—CYP2D6—Metabolism—EP300—hematologic cancer	1.8e-06	1.14e-05	CbGpPWpGaD
Pergolide—ADRA1A—Signaling Pathways—TP53—hematologic cancer	1.78e-06	1.13e-05	CbGpPWpGaD
Pergolide—HTR1A—Signaling Pathways—AKT1—hematologic cancer	1.78e-06	1.12e-05	CbGpPWpGaD
Pergolide—HTR2C—Signaling Pathways—AKT1—hematologic cancer	1.77e-06	1.12e-05	CbGpPWpGaD
Pergolide—DRD2—Signaling Pathways—HRAS—hematologic cancer	1.77e-06	1.12e-05	CbGpPWpGaD
Pergolide—HTR2A—Signaling Pathways—HRAS—hematologic cancer	1.74e-06	1.1e-05	CbGpPWpGaD
Pergolide—CYP3A4—Metabolism—CREBBP—hematologic cancer	1.73e-06	1.09e-05	CbGpPWpGaD
Pergolide—ADRA2C—Signaling Pathways—AKT1—hematologic cancer	1.72e-06	1.09e-05	CbGpPWpGaD
Pergolide—ADRA2A—Signaling Pathways—PIK3CA—hematologic cancer	1.71e-06	1.08e-05	CbGpPWpGaD
Pergolide—ADRA1A—Signaling Pathways—HRAS—hematologic cancer	1.71e-06	1.08e-05	CbGpPWpGaD
Pergolide—ADRA1B—Signaling Pathways—AKT1—hematologic cancer	1.69e-06	1.07e-05	CbGpPWpGaD
Pergolide—DRD2—Signaling Pathways—IL6—hematologic cancer	1.69e-06	1.07e-05	CbGpPWpGaD
Pergolide—ADRA2A—Metabolism—AKT1—hematologic cancer	1.67e-06	1.06e-05	CbGpPWpGaD
Pergolide—HTR2A—Signaling Pathways—IL6—hematologic cancer	1.67e-06	1.05e-05	CbGpPWpGaD
Pergolide—ADRA2A—Signaling Pathways—TP53—hematologic cancer	1.66e-06	1.05e-05	CbGpPWpGaD
Pergolide—CYP3A4—Metabolism—PIK3CD—hematologic cancer	1.64e-06	1.04e-05	CbGpPWpGaD
Pergolide—ADRA1A—Signaling Pathways—IL6—hematologic cancer	1.63e-06	1.03e-05	CbGpPWpGaD
Pergolide—CYP3A4—Metabolism—ALB—hematologic cancer	1.62e-06	1.02e-05	CbGpPWpGaD
Pergolide—ADRA2A—Signaling Pathways—HRAS—hematologic cancer	1.58e-06	1e-05	CbGpPWpGaD
Pergolide—DRD2—Signaling Pathways—AKT1—hematologic cancer	1.56e-06	9.87e-06	CbGpPWpGaD
Pergolide—CYP3A4—Metabolism—PIK3R1—hematologic cancer	1.55e-06	9.8e-06	CbGpPWpGaD
Pergolide—HTR2A—Signaling Pathways—AKT1—hematologic cancer	1.54e-06	9.72e-06	CbGpPWpGaD
Pergolide—ADRA2A—Signaling Pathways—IL6—hematologic cancer	1.52e-06	9.58e-06	CbGpPWpGaD
Pergolide—ADRA1A—Signaling Pathways—AKT1—hematologic cancer	1.51e-06	9.51e-06	CbGpPWpGaD
Pergolide—CYP3A4—Metabolism—PIK3CB—hematologic cancer	1.43e-06	9.04e-06	CbGpPWpGaD
Pergolide—ADRA2A—Signaling Pathways—AKT1—hematologic cancer	1.4e-06	8.84e-06	CbGpPWpGaD
Pergolide—CYP2D6—Metabolism—PIK3CA—hematologic cancer	1.33e-06	8.43e-06	CbGpPWpGaD
Pergolide—CYP3A4—Metabolism—PTEN—hematologic cancer	1.24e-06	7.81e-06	CbGpPWpGaD
Pergolide—CYP3A4—Metabolism—EP300—hematologic cancer	1.18e-06	7.45e-06	CbGpPWpGaD
Pergolide—CYP2D6—Metabolism—AKT1—hematologic cancer	1.09e-06	6.89e-06	CbGpPWpGaD
Pergolide—CYP3A4—Metabolism—PIK3CA—hematologic cancer	8.72e-07	5.51e-06	CbGpPWpGaD
Pergolide—CYP3A4—Metabolism—AKT1—hematologic cancer	7.13e-07	4.5e-06	CbGpPWpGaD
